Precigen (NASDAQ:PGEN) Director Jeffrey Kindler Sells 106,837 Shares

Precigen, Inc. (NASDAQ:PGEN) Director Jeffrey Kindler sold 106,837 shares of Precigen stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $3.38, for a total transaction of $361,109.06. Following the completion of the sale, the director owned 346,070 shares in the company, valued at approximately $1,169,716.60. This trade represents a 23.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Precigen Stock Up 1.5%

NASDAQ:PGEN opened at $3.34 on Thursday. The stock has a market cap of $995.22 million, a P/E ratio of -7.95 and a beta of 1.61. The firm’s fifty day simple moving average is $3.21 and its 200 day simple moving average is $2.10. Precigen, Inc. has a twelve month low of $0.65 and a twelve month high of $5.22.

Precigen (NASDAQ:PGEN) last announced its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.67 million. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%. On average, analysts expect that Precigen, Inc. will post -0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Precigen

A number of hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in shares of Precigen in the fourth quarter worth $27,000. Apella Capital LLC purchased a new position in shares of Precigen in the first quarter worth $40,000. Voya Investment Management LLC raised its position in Precigen by 142.9% in the 1st quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company’s stock worth $55,000 after buying an additional 21,633 shares during the last quarter. ProShare Advisors LLC raised its position in Precigen by 26.6% in the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock worth $58,000 after buying an additional 10,900 shares during the last quarter. Finally, Strs Ohio purchased a new position in Precigen in the 1st quarter worth about $70,000. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PGEN has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $8.50 price target on shares of Precigen in a research report on Tuesday, August 19th. JMP Securities boosted their price objective on shares of Precigen from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 19th. JPMorgan Chase & Co. raised shares of Precigen from an “underweight” rating to a “neutral” rating in a research note on Friday, August 15th. Wall Street Zen raised Precigen from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. Finally, Citigroup restated an “outperform” rating on shares of Precigen in a research note on Tuesday, August 19th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.25.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.